Literature DB >> 24813299

CD8(+) granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency.

Bryan Gammon1, Alistair Robson2, Janyana Deonizio3, Lisa Arkin3, Joan Guitart3.   

Abstract

BACKGROUND: Granulomatous cutaneous T-cell lymphoma (G-CTCL) is a rarely encountered entity. Most G-CTCL is CD4(+), with granulomatous mycosis fungoides representing the vast majority of cases. Because of the rarity of CD8(+) G-CTCL, there is a paucity of data regarding the clinicopathologic features and expected course.
OBJECTIVE: To describe the clinical and histopathologic features of G-CTCL.
METHODS: This is a retrospective review of collected cases.
RESULTS: We present 4 cases of CD8(+) G-CTCL. Patients presented with papules and nodules on the trunk and extremities without antecedent patch or plaque disease. In all cases, biopsy specimens were obtained, and these revealed a dense granulomatous infiltrate accompanied by an atypical lymphoid infiltrate of CD8(+) T cells. T-cell clonality studies were positive in 3 of 4 cases. Staging was negative for nodal involvement, but lung granulomas were seen in all cases. In all 4 cases, the patient's medical history was significant for immunodeficiency, either primary or iatrogenic. All 4 patients had slowly progressive disease. LIMITATIONS: This is a small retrospective case series.
CONCLUSIONS: CD8(+) G-CTCL appears to be associated with immunodeficiency. The finding of a CD8(+) G-CTCL should prompt an evaluation for underlying immunodeficiency. Additional studies are required to validate these conclusions.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  X-linked agammaglobulinemia; common variable immunodeficiency; cutaneous T-cell lymphoma; cytotoxic; granulomatous; immunodeficiency; mycosis fungoides

Mesh:

Year:  2014        PMID: 24813299     DOI: 10.1016/j.jaad.2014.03.028

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  8 in total

Review 1.  [Cutaneous lymphomas: new entities and rare variants].

Authors:  W Kempf; C Mitteldorf
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 2.  [Granulomatous reaction pattern of the skin : Interstitial granulomatous dermatitis - lymphoma - vasculitis].

Authors:  C Rose; K Holl-Ulrich
Journal:  Hautarzt       Date:  2017-07       Impact factor: 0.751

3.  High-throughput sequencing reveals an altered T cell repertoire in X-linked agammaglobulinemia.

Authors:  Manish Ramesh; Noa Simchoni; David Hamm; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2015-09-07       Impact factor: 3.969

4.  Indolent cytotoxic T cell lymphoproliferation associated with nodular regenerative hyperplasia: a common liver lesion in the context of common variable immunodeficiency disorder.

Authors:  Vanessa Szablewski; Céline René; Valérie Costes
Journal:  Virchows Arch       Date:  2015-10-22       Impact factor: 4.064

5.  Primary/Congenital Immunodeficiency: 2015 SH/EAHP Workshop Report-Part 5.

Authors:  Dita Gratzinger; Elaine S Jaffe; Amy Chadburn; John K C Chan; Daphne de Jong; John R Goodlad; Jonathan Said; Yasodha Natkunam
Journal:  Am J Clin Pathol       Date:  2017-02-01       Impact factor: 2.493

Review 6.  Common Variable Immunodeficiency and Gastric Malignancies.

Authors:  Patrizia Leone; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Int J Mol Sci       Date:  2018-02-02       Impact factor: 5.923

7.  An accurate diagnosis of dermal CD8+ lymphoproliferative disorders requires clinicopathological and immunophenotypic correlation.

Authors:  Alejandro A Gru
Journal:  Br J Dermatol       Date:  2022-05       Impact factor: 11.113

8.  A Systematic Review on Predisposition to Lymphoid (B and T cell) Neoplasias in Patients With Primary Immunodeficiencies and Immune Dysregulatory Disorders (Inborn Errors of Immunity).

Authors:  Irbaz Bin Riaz; Warda Faridi; Mrinal M Patnaik; Roshini S Abraham
Journal:  Front Immunol       Date:  2019-04-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.